Abstract
Thirty-six children with brain tumors were treated with surgery, radiation and/or adjuvant chemotherapy. After tumor recurrence, cisplatin (60 mg/m2/day IV×2) was given every three to four weeks. CT scans were used to measure drug response prior to the first, third and fifth courses. Complete and partial responses were demonstrated in nine of 31 evaluable patients. Dose limiting toxicities were renal and auditory. Seven patients developed the syndrome of inappropriate antidiuretic horm one secretion. This study confirms that cisplatin is active in a spectrum of brain tumors.
Similar content being viewed by others
References
Highby D, Wallace HJ, Albert DJ: Diamminodichloroplatinum in the chemotherapy of testicular tumors. J Urol 112:100–104, 1974
Einhorn LH, Williams SD: The role of cis-platinum in solid tumor therapy. N Engl J Med 300:289–291, 1979
Kamalakar P, Freeman AI, Highby DJ: Clinical response and toxicity with cis-dichlorodiammineplatinum (II) in children. Cancer Treat Rep 61:835–839, 1977
Gaynon P, Baum E, Greenberg L: A phase II trial of cisplatinum diammine dichloride (DDP) (NSC 117825) in refractory childhood tumors. Proc Am Soc Clin Oncol 20:394, 1979
Stewart DJ, Leavens M, Maor M, Fenn L, Luna M, Bonura J, Caprioloi R, Loo T, Benjamin S: Human central nervous system distribution of cis-diamminedichloroplatinum and use of as a radiosensitizer in malignant brain tumors. Cancer Res 42:2474–2479, 1982
Khan AB, D'Souza BJ, Wharam MD, Champion AA, Sinks LF, Woo SY, McCullough DC, Leventhal BG: Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep 66:2013–2020, 1982
Sexauer CL, Khan A, Burger PC, Krischer JP, Van Eys J, Vats T, Ragab AH: Cisplatin in recurrent pediatric brain tumors. A POG phase 11 study. A pediatric oncology group study. Cancer 56:1497–1501, 1985
Diez B, Menges J, Muriel FS: Evaluation of cisplatinum in children with recurrent brain tumors. Cancer Treat Rep 69:911–913, 1985
Sterrett PR, Thompson AM, Chapman AL, Matzke HA: The effects of hyperosmolarity on the blood-brain barrier. A morphological and physiological correlation. Brain Res 77:281–295, 1974
Stewart DJ, Richard MT, Hugenholtz H, Dennery J, Nundy D, Prior J, Montpetit V, Hopkins HS: Penetration of teniposide (VM 26) into human intracerebral tumors. J Neuro-Oncol 2:315–324, 1984
Hasegawa H, Allen JC, Mehta BM, Shapiro WR, Posner JG: Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis. Neurology 29:1280–1286, 1979
Granowetter L, Rosenstock JG, Packer RJ: Enhanced cisplatinum neurotoxcity in pediatric patients with brain tumors. J Neuro-Oncol 1:293–297, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bertolone, S.J., Baum, E.S., Krivit, W. et al. A phase II study of cisplatin therapy in recurrent childhood brain tumors. J Neuro-Oncol 7, 5–11 (1989). https://doi.org/10.1007/BF00149372
Issue Date:
DOI: https://doi.org/10.1007/BF00149372